grasustek
juta pharma gmbh - pegfilgrastim - neutropenie - immunostimulants, - vermindering van de duur van neutropenie en de incidentie van febriele neutropenie bij volwassen patiënten die werden behandeld met cytotoxische chemotherapie voor maligniteit (met uitzondering van chronische myeloïde leukemie en myelodysplastische syndromen).
insulin aspart sanofi
sanofi winthrop industrie - insuline aspart - suikerziekte - geneesmiddelen die worden gebruikt bij diabetes - insulin aspart sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.
byooviz
samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologica - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
sondelbay
accord healthcare s.l.u. - teriparatide - osteoporose - calcium homeostase - sondelbay is indicated in adults. behandeling van osteoporose bij postmenopauzale vrouwen en bij mannen met een verhoogd risico op fracturen. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. de behandeling van osteoporose in verband met de aanhoudende systemische glucocorticoïden therapie bij vrouwen en mannen met een verhoogd risico op fracturen.
truvelog mix 30
sanofi winthrop industrie - insuline aspart - suikerziekte - geneesmiddelen die worden gebruikt bij diabetes - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
stimufend
fresenius kabi deutschland gmbh - pegfilgrastim - neutropenie - immunostimulants, , kolonie stimulerende factoren - vermindering van de duur van neutropenie en de incidentie van febriele neutropenie bij volwassen patiënten die werden behandeld met cytotoxische chemotherapie voor maligniteit (met uitzondering van chronische myeloïde leukemie en myelodysplastische syndromen).
inpremzia
baxter holding b.v. - insulin human (rdna) - suikerziekte - geneesmiddelen die worden gebruikt bij diabetes - inpremzia is indicated for the treatment of diabetes mellitus.
ximluci
stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).
ranivisio
midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologica - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).
kauliv
strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostase - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.